Founded in 2015 by Dr. Tyler Jacks, head of the Koch Institute at MIT, Dr. David Raulet, one of the world's leading experts in Natural Killer (NK) cell biology, and Bill Haney, a longtime tech entrepreneur and investor, Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system. Our therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies – such as T cell treatments. Dragonfly’s Scientific Advisory Board and founders are major figures in cancer biology and immunology, and launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.
